Photo by nci from unsplash
3556Background: Apatinib, an oral VEGFR2 inhibitor, has been approved as third line treatment for metastatic gastric cancer in China. The aim of this study was to evaluate the efficacy and… Click to show full abstract
3556Background: Apatinib, an oral VEGFR2 inhibitor, has been approved as third line treatment for metastatic gastric cancer in China. The aim of this study was to evaluate the efficacy and safety o...
Keywords:
salvage treatment;
treatment;
treatment refractory;
apatinib salvage;
refractory metastatic;
cancer
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!